Pb. Desai et al., REVERSAL OF DOXORUBICIN RESISTANCE IN MULTIDRUG-RESISTANT MELANOMA-CELLS IN-VITRO AND IN-VIVO BY DIPYRIDAMOLE, Methods and findings in experimental and clinical pharmacology, 19(4), 1997, pp. 231-239
The occurrence of multidrug resistance (MDR) decreases the clinical ut
ility of several anticancer agents, including doxorubicin (DOX). A tra
nsmembrane efflux pump, P-glycoprotein (P-gp), is frequently implicate
d in the development of MDR in tumor cells. Dipyridamole (DP), a clini
cally used antiplatelet drug, enhances the cytotoxicity of the antican
cer drugs affected by MDR, Although this aspect has been studied exten
sively in cell culture models, the effectiveness of DP to overcome mul
tidrug resistance has not been investigated using in vivo models of mu
ltidrug-resistant solid tumors. Therefore, the objective of this study
was to evaluate the role of DP in the reversal of resistance to DOX i
n tumor-bearing mice in the context of its anti-MDR activity in vitro.
For this purpose, drug-sensitive murine melanoma cells (B16V) and the
ir DOX-selected MDR variant, B16VDXR cells, were used In vitro, the re
versal of DOX resistance of B16VDXR cells by DP was determined using c
lonogenic assays, and the influence of DP on the transport of DOX was
evaluated by measurement of steady-state accumulation as weil as efflu
x of DOX in B16VDXR cells. Antitumor activity of different treatments
was assessed by monitoring tumor growth. Pharmacokinetics of DOX, with
or without DP, were evaluated in C57BL/6 mire bearing B16V or B16VDXR
tumors. DP produced a 6.4-fold reversal of resistance to DOX in vitro
; this was accompanied by an increase (3.6-fold) iii the steady-state
intracellular accumulation of DOX and a marked reduction in the efflux
of DOX from B16VDXR cells. Furthermore, a linear correlation was obse
rved between the EC50 values and the steady-state intracellular levels
of DOX in the multidrug-resistant cells. In the in vivo experiments,
similar growth patterns were seen for the DOX alone and the DOX+DP gro
ups for B16V tumors. The results with B16VDXR tumors were in sharp con
trast. The DOX+DP treatment caused a significant delay in the growth o
f B16VDXR tumors compared to treatment with DOX alone or controls. DP
did not alter the plasma pharmacokinetics of DOX in C57BL/6 mice but r
esulted in a significant increase in the intratumoral accumulation of
DOX.